RTD Momentum Masks a Broken Profit Model
Fratelli doubled RTD cases to nearly 100,000, but Q2 flat revenue and ₹6.3 crore net loss expose the flaw: EBITDA breakeven plus high debt means no path to profit until FY28 at earliest. Management has abandoned prior guidance and is now managing down expectations.
-₹6.3 Cr
-90.7% YoY
₹1.4 Cr
1.5% margin
~₹2 Cr/qtr
Eating profit despite EBITDA breakeven
The surface narrative is RTD momentum: Shotgun doubled to nearly 100,000 cases in H1, revenue ₹18 crore (from ₹8.5 crore prior). But beneath that sits a harder truth—the income statement doesn't reconcile. H1 EBITDA is ₹1.4 crore, yet Q2 net loss is ₹6.3 crore. The gap is a high debt burden: roughly ₹1–2 crore per quarter in interest and D&A. For a ₹45 crore revenue quarter on the edge of flat growth, that math breaks.
Management's claims—what holds up
Shotgun RTD is on track; 100k cases achieved, heading to 200k FY27
Confirmed. H1 RTD ~100k cases, revenue ₹18 Cr (doubled from ₹8.5 Cr prior year). Distribution footprint (32k touchpoints) supports volume ambition.
Supported
EBITDA improved; H1 moved from loss ₹1 Cr to profit ₹1.4 Cr
Confirmed on EBITDA; but Q2 net loss ₹6.3 Cr shows D&A/interest burden ~₹2 Cr/qtr is material. EBITDA breakeven does not translate to profit.
Supported (on EBITDA); misleading for profit
Gross margin guidance 77–80% remains intact
Q2 gross margin fell to 76.7% due to RTD mix (RTD at ~76% vs premium 80%+). RTD is ~40% of revenue now. Guidance claim is at odds with Q2 result and current mix.
Overstated
Revenue growth is on track; H1 up 10%
H1 +10% is real, but Q2 flat (-1.4% YoY). Momentum stalled. Growth is RTD (emerging category) not core wine (down in premium/UP market).
Supported on H1; contradicted on momentum
Net profitability expected Q1/Q2 FY28, not FY27
Implies full FY27 remains loss-making. Management de facto abandoned prior implicit target of FY27 recovery. Profitability timeline slipped ~18 months.
Candid; signals execution miss vs prior calls
What changed from prior quarters
Profitability timeline slipped: FY27 recovery → FY28 Q1/Q2 (~18 months delayed)
EBITDA margin guidance abandoned: Prior 10–12% FY27 target → now 1.5% H1, no reaffirmed forecast
RTD strategy crystallized: Shotgun now ~40% of revenue at 76% margin (vs premium 80%+)
Excise policy headwinds extended: UP (key market) down 30% H1, not contained to Q1
Cash flow stress acknowledged: ₹18 Cr VAT refund stuck; rights issue (₹29.87 Cr) raised to ease debt
The bull-bear ledger
RTD is real growth: 100k cases in H1, doubled in 6 months, on track to 200k FY27. New occasion, younger consumers.
Luxury (JNOON) holds pricing power: +23% H1 despite excise headwinds. Brand equity intact.
International expansion credible: 18 countries (4 new in H1); TASMAC Tamil Nadu, Jammu/Kashmir on roadmap.
Distribution moat is real: 32,000 retail touchpoints; 65% HoReCa revenue, strong channel position.
BUT: Q2 flat revenue (-1.4% YoY) breaks the growth narrative. RTD gains offset by core wine decline (UP down 30%).
BUT: Gross margin compressed 230bp due to RTD mix. RTD at 76% margin vs 80%+ premium; marketing spend 9–10% of RTD sales inflates opex.
BUT: PAT loss ₹6.3 Cr on flat revenue. High D&A/interest burden (~₹2 Cr/qtr) breaks profit despite EBITDA breakeven.
BUT: Cash flow remains tight (₹5 Cr H1) despite EBITDA profit. Inventory buildup, ₹18 Cr VAT stuck, high DSO—working capital drain.
BUT: Prior 10–12% EBITDA margin guidance far off-track (now 1.5%). Management deferring FY27 guidance to Q3, signaling low confidence.
BUT: Regulatory risk is structural. UP down 30%; recovery timing unclear. Premium segment most exposed.
How the street is positioned
At ₹107.1 (as of Nov 13), Fratelli is down 78% from its all-time high of ₹494.8 but holding above its 200-day average (₹99.53). The stock sits 9.7% below its 20-day SMA (₹118.36), signaling recent weakness but not capitulation. RSI at 33.7 is neutral—not oversold. Volume is normal. The market has priced in pain, but not total loss of faith.
Ownership is flat. FII hold 0.48%, DII 0%, and promoters 57.19%—no meaningful institutional flow QoQ. This is a retail/promoter-held story, not one attracting institutional capital. The absence of FII/DII buying on a 78% drawdown suggests institutions are waiting for a clearer path to profitability before committing. Promoters are holding steady (no recent exits), which is a mild positive—they haven't abandoned ship.
Risks ranked (by how much they should concern a holder)
Profitability slip: FY28 breakeven misses or slips to FY29
HighManagement has already slipped from FY27 to FY28. If FY28 execution stumbles (RTD scaling, margin recovery, debt paydown), credibility collapses and stock re-rates lower.
Regulatory headwinds (excise policy) persist or worsen
HighUP (key market) down 30% H1 due to excise policy. If Q3/Q4 show no relief and other states follow, revenue base shrinks further. Premium segment most exposed.
RTD profitability unproven; unit economics opaque
HighRTD margin ~76% (vs 80%+ premium). Marketing spend 9–10% of RTD sales is high. If RTD becomes >50% of revenue and margin doesn't recover, blended margin declines further.
Cash flow remains tight; debt service constrains capex
HighH1 operating CF only ₹5 Cr despite EBITDA ₹1.4 Cr. Inventory buildup, ₹18 Cr VAT stuck, DSO high. Rights issue (₹29.87 Cr) will help, but working capital recovery takes 2–3 quarters.
Gross margin doesn't recover to 79–80% as RTD scales
MediumIf RTD margin stays at 76% and volume grows, blended margin can only decline. CFO claims margin will 'normalize' but no timeline or evidence provided.
Import competition post India-EU FTA pressures premium pricing
MediumFTA duty reductions (imported wines to 150% from prior) could increase availability. Pricing pressure on premium segment (JNOON, Sette) is a tail risk.
What to watch next (catalysts over 2–3 quarters)
1 · Q3 FY27 guidance revision (expected soon)
Management deferred full-year revenue/margin guidance to Q3. The Nov-Jan update will signal confidence (raised) or caution (held/lowered). If guidance is again lowered or deferred, credibility collapses.
2 · TASMAC Tamil Nadu rollout and RTD ramp (Q3/Q4)
Shotgun enters Tamil Nadu TASMAC next quarter; also rolling out ethnic flavors. These are needle-movers for RTD volume. Acceleration toward 200k cases by year-end would validate the strategy.
3 · Operating CF recovery and debt trajectory (H2 FY27)
Rights issue (₹29.87 Cr) closes by January 2027. VAT refunds (₹18 Cr stuck) expected 'next year or so.' If working capital improves and operating CF rises to ₹10–15 Cr/qtr, debt paydown becomes credible and FY28 profitability thesis gains traction.
The honest read
Fratelli is in the middle of a strategic pivot—RTD is real, luxury is intact, and distribution is world-class. But the near-term profit math is broken, and management has missed its prior targets by a wide margin. The 10–12% EBITDA margin guidance for FY27 is now abandoned; H1 shows 1.5%. Profitability is delayed to FY28 at best.
This is not a step-change in the business. It's a company navigating a regulatory headwind (UP excise), executing a product pivot (RTD), and trying to escape a debt burden (₹2 Cr interest/qtr). Each is solvable. But they're moving in different directions—new product pulls margin down, regulatory headwind pulls revenue down, and debt pulls profit down.
At ₹107.1, the stock has priced in a lot of pain (down 78% from ATH). The debate is no longer 'will this work?' but 'will it work fast enough?' If FY28 Q1/Q2 shows net profit breakeven and RTD cases hit 150k+, the thesis works. If profitability slips to FY29 or RTD plateaus below 150k, the stock re-rates lower.
For a current holder, this is a Hold. The thesis is intact, but it's a 'show me' story now. For a buyer, wait for Q3 guidance (expected soon) or early FY28 signals before stepping in. The single number to track: operating cash flow. If H1 ₹5 Cr grows to ₹10–15 Cr/qtr by year-end (post rights issue and VAT refund), that's the green light. If it stays flat or declines, the debt spiral continues and the FY28 breakeven thesis falters.
Informational and educational content only. Not investment advice.